Bureaucrats Shouldn’t Decide What Counts as Innovation

CMS should withdraw this provision that would prematurely combine separately developed and separately approved medicines for purposes of government price setting.

President Donald Trump returned to office determined to lower prices, bring manufacturing back to the United States, and unleash American innovation.

His policies are already producing results. Pharmaceutical companies have announced roughly $500 billion in new American investments in research, manufacturing, and infrastructure. President Trump has also …